Business UpdateJul 21, 2026, 06:08 AM
Alterity to Participate in BTIG Biotechnology Conference
AI Summary
Alterity Therapeutics announced its participation in the virtual BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. CEO David Stamler, M.D., will host one-on-one meetings with investors during the event. The company, a clinical-stage biotechnology firm, is focused on developing disease-modifying treatments for neurodegenerative diseases, including preparing for a Phase 3 pivotal trial for its lead asset, ATH434, in Multiple System Atrophy (MSA).
Key Highlights
- Alterity Therapeutics will participate in the virtual BTIG Biotechnology Conference 2026.
- CEO David Stamler, M.D., will host 1-on-1 meetings with investors in the United States.
- The conference is scheduled to take place virtually from July 28-29, 2026.
- The company is focused on developing treatments for neurodegenerative diseases.
- Alterity is preparing to initiate a Phase 3 pivotal trial for ATH434 in Multiple System Atrophy (MSA).
Price Impact
More from ATHE